Natco Pharma's Canadian Unit, Celgene Sign Pact For Cancer Treatment Drug
Natco Pharma on Friday said its Canadian subsidiary has entered into a settlement agreement with biopharmaceutical firm Celgene (part of Bristol-Myers Squibb) for Lenalidomide capsules.
Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells.
"Natco Pharma (Canada) Inc., Canada, a subsidiary of Natco Pharma Ltd has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide Capsules in Canada," the company said in a regulatory filing.
The terms of the agreement are confidential as per the agreement, the company added.
Shares of Natco Pharma were trading 0.15 per cent lower at Rs 676.50 apiece on BSE.
Monzo Looks For US Banking License
Monzo is preparing a renewed push to secure a US banking licence, four years after abandoning its first attempt when tal... Read more
Crypto Firms Push Into US Banking
America’s cryptocurrency companies are scrambling to secure a foothold in the country’s traditional banking system, ... Read more
Parallel Banking: Stablecoins Are Now Global
Parallel Banking: How Stablecoins Are Building a New Global Payments SystemStablecoins—digital currencies pegged to tr... Read more
JPMorgan Deploys AI Chatbot To Revolutionize Research And Productivity
JPMorgan has deployed an AI-based research analyst chatbot to enhance productivity among its workforce, with approximate... Read more
Private Equity And Banks: The Complex Web Of Leverage
Private equity has emerged as a significant force in the global financial landscape, driving substantial growth and inve... Read more
Financial Watchdog Highlights Unresolved Vulnerabilities In Shadow Banking Sector
The world’s leading financial stability watchdog has issued a warning about the unresolved vulnerabilities within the ... Read more